Myriad Genetics

$26.70 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Myriad Genetics

Myriad Genetics, Inc. is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk for developing disease later in life, identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to enable optimal treatment, or assess a patient's risk of disease progression and disease recurrence. The other segment provides testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services, such as finance, human resources, legal and information technology. Its molecular diagnostic tests include myRisk Hereditary Cancer, BRACAnalysis CDx and COLARIS.

Stock Analysis

last close $26.7
1-mo return 37.6%
3-mo return 34.5%
avg daily vol. 614.05T
52-week high 36.95
52-week low 16.02
market cap. $2.2B
forward pe 140.5
annual div. -
roe -1.9%
ltg forecast -
dividend yield -
annual rev. $672M
inst own. -

Subscribe now for daily local and international financial news